|
You are here: Home: BCU 7|2002: Debu Tripathy,
MD: Select
publications
Select publications
The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’
Group. Anastrozole alone or in combination with tamoxifen
versus tamoxifen alone for adjuvant treatment of postmenopausal
women with early breast cancer: First results of the ATAC randomised
trial. Lancet 2002;359:2131–9. Abstract
Balducci L et al. Management of breast cancer in the older
woman. Cancer Control 2001;8(5):431-41. Abstract
Boyages J et al. Use of the St Gallen classification for
patients with node-negative breast cancer may lead to overuse of
adjuvant chemotherapy. Br J Surg 2002;89(6):789-96. Abstract
Bundred N, Howell A. Fulvestrant (Faslodex): Current status
in the therapy of breast cancer. Expert Rev Anticancer
Ther 2002;2(2):151-60. Abstract
Burstein HJ et al. Clinical activity of trastuzumab and
vinorelbine in women with HER2- overexpressing metastatic breast
cancer. J Clin Oncol 2001;19(10):2722-30. Abstract
Carlson RW. Sequencing of endocrine therapies in breast
cancer--integration of recent data. Breast Cancer Res Treat
2002;75 Suppl 1:S27-32; discussion S33-5. No abstract available.
Endocrine responsiveness and tailoring adjuvant therapy
for postmenopausal lymph node-negative breast cancer: A randomized
trial. J Natl Cancer Inst 2002;94(14):1054-65. Abstract.
Houghton J et al. The ZIPP trial of adjuvant Zoladex in
premenopausal patients with early breast cancer: An update at five
years. Proc ASCO 2000;Abstract
359
Howell A et al. Fulvestrant, formerly ICI 182,780, is
as effective as anastrozole in postmenopausal women with advanced
breast cancer progressing after prior endocrine treatment.
J Clin Oncol 2002;20:3396-403. Abstract
Jones SE. A new estrogen receptor antagonist--an overview
of available data. Breast Cancer Res Treat 2002;75 Suppl
1:S19-21; discussion S33-5. No abstract available.
Jones SE et al. Adjuvant chemotherapy with doxorubicin
and cyclophosphamide in women with rapidly proliferating node-negative
breast cancer. Clin Breast Cancer 2002;3(2):147-52. Abstract
Leyland-Jones B. Dose scheduling--Herceptin.
Oncology 2001;61 Suppl 2:31-6. Abstract
Ligibel JA and Winer EP. Trastuzumab/chemotherapy combinations
in metastatic breast cancer. Semin Oncol 2002;29(3 Suppl
11):38-43. Abstract
Osborne CK et al. Double-blind, randomized trial comparing
the efficacy and tolerability of fulvestrant versus anastrozole
in postmenopausal women with advanced breast cancer progressing
on prior endocrine therapy: Results of a North American trial. J
Clin Oncol 2002;20:3386-95. Abstract
Paik S et al. Real-world performance of HER2 testing—National
Surgical Adjuvant Breast and Bowel Project experience.
J Natl Cancer Inst 2002;94:852-4. Abstract
Pegram MD et al. Phase II study of receptor-enhanced chemosensitivity
using recombinant humanized anti-p185HER2/neu monoclonal antibody
plus cisplatin in patients with HER2/neuoverexpressing metastatic
breast cancer refractory to chemotherapy treatment. J Clin
Oncol 1998;16(8):2659-71. Abstract
Pegram MD, Slamon DJ. Combination therapy with trastuzumab
(Herceptin) and cisplatin for chemoresistant metastatic breast cancer:
Evidence for receptor-enhanced chemosensitivity. Semin
Oncol 1999;26(4 Suppl 12):89-95. Abstract
Recht A et al. Postmastectomy radiotherapy: Guidelines
of the American Society of Clinical Oncology. J Clin Oncol
2001;19:1539-69. Abstract
Roche PC et al. Concordance between local and central
laboratory HER2 testing in the breast Intergroup trial N9831. J
Natl Cancer Inst 2002;94:855-7. Abstract
|
